Indonesia Gastritis Treatment Market Size, Share, Trends and Forecasts 2031

Key Fndings

• The Indonesia Gastritis Treatment Market is expanding due to rising cases of acute and chronic gastritis linked to lifestyle, dietary habits, and infection prevalence.
• Growing awareness regarding Helicobacter pylori (H. pylori) infections is increasing diagnosis and treatment rates.
• Advancements in proton pump inhibitors (PPIs), H2 blockers, and targeted antibiotics are improving therapeutic outcomes in Indonesia.
• Increasing demand for minimally invasive diagnostic procedures such as endoscopy is supporting early intervention.
• The geriatric population, which is more susceptible to gastric disorders, is contributing significantly to market growth.
• Pharmaceutical innovation in combination therapies for drug-resistant H. pylori strains is shaping treatment protocols.
• Rising focus on patient-centric care and personalized gastrointestinal therapies is driving market modernization in Indonesia.
• Collaborations between pharmaceutical companies and healthcare institutions are accelerating clinical research and treatment adoption.

Indonesia Gastritis Treatment Market Size and Forecast

The Indonesia Gastritis Treatment Market is projected to grow from USD 6.3 billion in 2025 to USD 10.8 billion by 2031, at a CAGR of 9.7% during the forecast period. Increasing incidence of gastritis due to stress, alcohol consumption, irregular eating patterns, and bacterial infections is boosting treatment demand in Indonesia. PPIs remain the first-line therapy, while antibiotic regimens for H. pylori eradication continue to evolve. The market benefits from advancements in gastrointestinal diagnostics, expanding hospital infrastructure, and growing patient preference for safe and effective treatment options. Enhanced reimbursement policies and the availability of innovative drugs will further support long-term market expansion in Indonesia.

Introduction

Gastritis refers to the inflammation of the stomach lining caused by factors such as infection, autoimmune reactions, prolonged NSAID use, excessive alcohol intake, and stress. In Indonesia, gastritis is becoming increasingly common due to lifestyle changes, rising urbanization, and dietary patterns high in acidity and irritants. Treatment involves medications such as antacids, H2 blockers, PPIs, and antibiotics, depending on the underlying cause. Improved diagnostic technologies like rapid urease tests, breath tests, and endoscopic imaging are enhancing detection accuracy. The healthcare system’s growing focus on gastrointestinal disorders is leading to greater awareness, better management, and improved patient outcomes in Indonesia.

Future Outlook

By 2031, the Indonesia Gastritis Treatment Market will experience strong momentum, driven by advanced therapies targeting drug-resistant H. pylori strains and personalized medicine approaches. Digital health solutions will support remote monitoring and symptom management, enabling earlier intervention. Minimally invasive endoscopic treatments and biomarker-based diagnostics will strengthen clinical decision-making. Pharmaceutical companies will invest heavily in novel antibiotic formulations, combination therapies, and acid-suppressive drugs with improved safety profiles. Public health campaigns addressing hygiene, dietary habits, and infection prevention will reduce disease burden. Indonesia is expected to become a key market for next-generation gastroenterology solutions, supported by robust healthcare investment and research collaborations.

Indonesia Gastritis Treatment Market Trends

• Rising Prevalence of H. pylori Infection
  H. pylori remains the leading cause of chronic gastritis, and its prevalence in Indonesia is driving extensive demand for antibiotic therapies and diagnostic testing. The infection is commonly spread through contaminated food and water, making it a major public health concern. Increasing screening programs and awareness initiatives are resulting in higher detection rates. Research is also expanding toward understanding antibiotic-resistant strains and developing more effective treatment combinations. As eradication therapy becomes a clinical priority, the market will continue to experience growing demand for advanced antibiotics, probiotics, and adjunct therapies to support long-term patient recovery.

• Growing Adoption of Proton Pump Inhibitors (PPIs)
  PPIs such as omeprazole, pantoprazole, and esomeprazole remain the gold standard for managing acid-induced gastritis in Indonesia. Their widespread adoption is driven by high efficacy, safety, and accessibility across healthcare facilities. With growing cases of reflux-related gastritis and NSAID-induced gastric irritation, PPI usage is expected to expand further. Long-term studies evaluating PPI safety profiles are guiding clinical practice and optimizing dosage recommendations. Manufacturers are introducing improved formulations to enhance patient compliance. This sustained reliance on PPIs ensures steady market demand across both hospital and retail pharmacy channels.

• Shift Toward Combination Therapies
  As antibiotic resistance increases, combination therapies that pair PPIs with dual or triple antibiotic regimens are becoming a standard approach in Indonesia. These therapies improve eradication success rates and reduce the recurrence of H. pylori infection. Pharmaceutical companies are developing advanced fixed-dose combinations to simplify treatment protocols. Physicians increasingly prefer combination regimens due to their proven efficacy in persistent and recurrent cases. As multidrug resistance continues to rise globally, the demand for effective combination therapies will grow significantly.

• Increasing Preference for Minimally Invasive Diagnostics
  Healthcare providers in Indonesia are adopting advanced diagnostic tools such as endoscopy, rapid urease tests, urea breath tests, and stool antigen tests. These methods offer improved accuracy and faster results, enabling timely treatment initiation. Technological advancements have enhanced endoscopic imaging quality, supporting better visualization of gastric mucosa. Growing awareness about early detection and rising investments in gastroenterology equipment are further accelerating this trend. Minimally invasive diagnostics are reducing patient discomfort and improving clinical outcomes, contributing to overall market growth.

• Growing Use of Probiotics and Adjunct Therapies
  Probiotics are gaining importance in gastritis management due to their ability to support gut flora balance and reduce antibiotic therapy side effects. In Indonesia, physicians are increasingly recommending probiotics alongside antibiotic regimens to improve treatment tolerance. Their role in preventing recurrence and enhancing gastric healing is being validated through clinical research. Adjunct therapies such as mucosal protectants and herbal extracts are also gaining acceptance. This diversification of treatment options supports better symptom control and long-term patient adherence.

Market Growth Drivers

• Increasing Prevalence of Gastritis and Peptic Disorders
  Lifestyle changes, stress, and unhealthy dietary habits in Indonesia are contributing to rising cases of gastritis and related gastrointestinal conditions. The widespread use of NSAIDs and increased alcohol consumption further elevate disease risk. Growing public awareness and improved access to healthcare facilities are resulting in higher diagnosis and treatment rates. The rising burden of chronic gastritis is compelling healthcare providers to expand gastroenterology services. This increasing patient population is a key driver for treatment demand and pharmaceutical innovation.

• Expansion of Healthcare Infrastructure
  The healthcare landscape in Indonesia is rapidly expanding with new hospitals, diagnostic centers, and gastroenterology units. This expansion ensures wider access to diagnostics, medications, and specialist care for gastritis patients. Government initiatives supporting healthcare modernization and insurance coverage are increasing treatment affordability. As healthcare infrastructure strengthens, diagnostic accuracy improves, enabling earlier and more effective intervention. This expanded access directly boosts demand for gastritis treatment solutions across all demographics.

• Advancements in Pharmaceutical Research
  Pharmaceutical companies are investing heavily in advanced PPIs, H2 blockers, antibiotics, and novel drug delivery systems. Research aims to develop therapies with improved efficacy, fewer side effects, and better resistance management. In Indonesia, collaborations between academic institutions and drug developers are accelerating clinical trials for new treatment combinations. These advancements improve treatment success rates and patient satisfaction. Ongoing innovation ensures continuous introduction of more effective therapeutic options, fueling market expansion.

• Rising Geriatric Population
  The elderly population in Indonesia is growing and has a higher susceptibility to gastrointestinal disorders, including gastritis. Age-related changes in digestive function, polypharmacy, and comorbidities increase the need for effective treatments. Healthcare providers are prioritizing gastroenterology services tailored to elderly patients' needs. The rising geriatric demographic ensures sustained long-term demand for gastritis diagnostics and medications. This trend is expected to significantly impact market growth over the next decade.

• Increasing Awareness and Diagnostic Rates
  Public health campaigns, improved sanitation, and educational programs are enhancing awareness of H. pylori infection and gastritis symptoms. In Indonesia, diagnostic rates have increased due to wider availability of endoscopy and non-invasive tests. Early detection allows timely treatment and reduces the risk of complications such as ulcers and gastric cancer. This shift toward proactive healthcare behavior supports market growth by increasing demand for medications and routine follow-up care.

Challenges in the Market

• Rising Antibiotic Resistance
  Increasing antibiotic resistance is one of the major challenges affecting H. pylori eradication in Indonesia. Resistance reduces treatment effectiveness and leads to recurrent infections, requiring more complex and costly therapies. Healthcare providers must frequently adjust treatment strategies to address resistant strains. Pharmaceutical manufacturers are under pressure to develop novel antibiotics and combination regimens. Until resistance management improves, treatment outcomes may remain inconsistent, creating obstacles for market expansion.

• Side Effects Associated with Long-Term PPI Use
  Although PPIs are widely used, long-term usage has been associated with potential side effects such as nutrient malabsorption, gastric polyps, and increased infection risk. These safety concerns may lead healthcare providers to reconsider dosage and duration of therapy. Patients may experience reduced compliance due to adverse effects. Continuous monitoring and updated clinical guidelines are required to ensure safe and effective PPI administration, posing challenges for market growth.

• Limited Access to Advanced Diagnostics in Rural Areas
  While urban regions of Indonesia have access to modern gastroenterology diagnostics, rural areas often lack advanced equipment and trained specialists. This disparity results in delayed diagnosis and inadequate treatment. Limited healthcare infrastructure in remote regions affects disease management and increases complication rates. Bridging this diagnostic gap requires improved investment in rural healthcare services. Until resolved, regional inequalities will continue to limit market penetration.

• High Cost of Branded Medications
  Branded PPIs and combination antibiotic therapies can be expensive, restricting access for low-income populations in Indonesia. High treatment costs lead patients to seek cheaper, less effective alternatives or discontinue treatment prematurely. This affects eradication success rates and increases the risk of chronic gastritis. Introducing affordable generics and expanding healthcare reimbursement will be crucial to overcoming this challenge.

• Insufficient Patient Compliance
  Gastritis treatment often requires multi-drug regimens, especially for H. pylori eradication. Poor adherence to therapy can reduce effectiveness, increase relapse rates, and contribute to antibiotic resistance. Many patients discontinue treatment due to symptom relief or medication side effects. Enhancing patient education and simplifying treatment protocols are essential strategies for improving outcomes. Without improved compliance, treatment efficacy will remain a significant barrier.

Indonesia Gastritis Treatment Market Segmentation

By Drug Class

• Proton Pump Inhibitors (PPIs)

• H2 Receptor Blockers

• Antacids

• Antibiotics

• Cytoprotective Agents

• Probiotics

By Disease Type

• Acute Gastritis

• Chronic Gastritis

• Erosive Gastritis

• Atrophic Gastritis

By Route of Administration

• Oral

• Intravenous

• Others

By End-User

• Hospitals

• Gastroenterology Clinics

• Retail Pharmacies

• Online Pharmacies

Leading Key Players

• AstraZeneca plc

• Takeda Pharmaceutical Company Limited

• Pfizer Inc.

• GlaxoSmithKline plc

• Dr. Reddy’s Laboratories Ltd.

• AbbVie Inc.

• Cipla Ltd.

• Novartis AG

• Sanofi S.A.

• Sun Pharmaceutical Industries Ltd.

Recent Developments

• AstraZeneca plc expanded research on next-generation PPIs targeting improved acid suppression and reduced long-term side effects in Indonesia.

• Takeda Pharmaceutical Company Limited introduced new combination therapies designed to address resistant H. pylori strains in Indonesia.

• Pfizer Inc. collaborated with healthcare institutions in Indonesia to enhance antibiotic stewardship programs for gastritis management.

• Cipla Ltd. launched cost-effective generic PPIs to improve treatment accessibility in rural and underserved regions of Indonesia.

• Sanofi S.A. advanced development of probiotic-based adjunct therapies to support recovery and reduce recurrence rates in Indonesia.

This Market Report Will Answer the Following Questions

1. What is the projected market size and growth rate of the Indonesia Gastritis Treatment Market by 2031?

2. Which therapies dominate the treatment landscape for gastritis in Indonesia?

3. How is antibiotic resistance influencing treatment protocols and drug development?

4. What diagnostic advancements are improving early detection and treatment outcomes?

5. Who are the leading market players and what strategies are they adopting in Indonesia?